SCHEMBL720172

SCHEMBL720172

COC(=O)c1ccc(NC(c2sc3cc(C(F)(F)F)cnc3c2C)C2CCCCC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
KDM4E B2RXH2 3/20 0.40
NPSR1 Q6W5P4 3/20 0.40
LMNA P02545 1/20 0.38
NPC1 O15118 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
EPHX2 P34913 1/20 0.37
GCG P01275 6/20 0.37
RAB9A P51151 1/20 0.36
CYP2C9 P11712 3/20 0.36
CYP2C19 P33261 3/20 0.36
MEN1 O00255 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
KMT2A Q03164 1/20 0.36
S1PR2 O95136 1/20 0.36
HPGD P15428 1/20 0.36
RCE1 Q9Y256 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL718728 0.91 RCE1 (0.44) ALDH1A1KDM4ENPSR1LMNAGCG
SCHEMBL720332 0.84 GCG (0.41) ALDH1A1GCGHPGD
SCHEMBL720373 0.83 GCG (0.36) ALDH1A1KDM4ENPSR1GCGMEN1
SCHEMBL719225 0.82 RCE1 (0.48) ALDH1A1NPSR1NPC1SMN1; SMN2EPHX2
SCHEMBL3101653 0.77 MAPK11 (0.40) ALDH1A1NPC1SMN1; SMN2EPHX2CYP2C9
SCHEMBL719528 0.77 RCE1 (0.39) EPHX2GCGRCE1
SCHEMBL720271 0.76 ALDH1A1 (0.41) ALDH1A1KDM4ELMNANPC1SMN1; SMN2
SCHEMBL720741 0.76 RCE1 (0.40) EPHX2GCGRCE1
SCHEMBL14905674 0.74 RCE1 (0.44) ALDH1A1KDM4ENPSR1NPC1SMN1; SMN2
SCHEMBL719453 0.72 RCE1 (0.60) ALDH1A1KDM4ENPC1RAB9ACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102015641-B Heterocyclic compound TAKEDA PHARMACEUTICAL 2014-01-01 CN disclosed
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
CN-102015641-A Heterocyclic compound TAKEDA PHARMACEUTICAL 2011-04-13 CN disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP ALDH1A1 504/4885KDM4E 1907/4885NPSR1 2548/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP ALDH1A1 504/4885KDM4E 1907/4885NPSR1 2548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.